S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
$3.98
+0.3%
$3.56
$1.42
$11.97
$234.42M1.51592,505 shs432,642 shs
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
$24.49
+12.2%
$23.68
$12.54
$28.91
$735.68M0.89377,730 shs698,554 shs
Chimerix, Inc. stock logo
CMRX
Chimerix
$0.93
+3.3%
$1.08
$0.88
$1.57
$83.17M1.15403,756 shs360,994 shs
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$0.63
+3.3%
$0.61
$0.45
$3.53
$14.92M1.93385,926 shs179,877 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$40.31
-3.2%
$45.00
$27.99
$50.99
$3.04B1.15403,527 shs324,121 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
+0.25%-9.55%+39.65%+29.22%-61.51%
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
+12.24%+8.84%-0.24%+37.97%+25.01%
Chimerix, Inc. stock logo
CMRX
Chimerix
+3.13%-5.83%-2.89%+0.84%-23.58%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
+3.40%+4.95%+12.03%+3.06%-81.64%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-3.17%-6.19%-9.11%-7.90%+6.08%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
2.16 of 5 stars
3.53.00.00.02.62.50.0
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
1.959 of 5 stars
3.42.00.00.02.43.30.0
Chimerix, Inc. stock logo
CMRX
Chimerix
4.0755 of 5 stars
3.54.00.04.12.01.70.6
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
1.2681 of 5 stars
0.04.00.03.92.80.80.6
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
1.5523 of 5 stars
3.52.00.00.01.92.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
3.00
Buy$9.33134.51% Upside
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
2.88
Moderate Buy$47.8895.49% Upside
Chimerix, Inc. stock logo
CMRX
Chimerix
3.00
Buy$8.00758.09% Upside
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$59.4447.47% Upside

Current Analyst Ratings

Latest ALDX, XENE, VBIV, BCYC, and CMRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$62.00
4/10/2024
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$43.00
4/10/2024
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$65.00
4/3/2024
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$10.00
4/2/2024
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
3/1/2024
Chimerix, Inc. stock logo
CMRX
Chimerix
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00
3/1/2024
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$56.00 ➝ $55.00
3/1/2024
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$46.00 ➝ $51.00
3/1/2024
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $62.00
2/21/2024
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00
2/21/2024
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$43.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/A$2.04 per shareN/A
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
$26.98M27.27N/AN/A$12.35 per share1.98
Chimerix, Inc. stock logo
CMRX
Chimerix
$320K259.91N/AN/A$2.17 per share0.43
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$8.68M1.72N/AN/A$7.46 per share0.08
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$9.43M322.44N/AN/A$14.18 per share2.84

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
-$37.54M-$0.64N/AN/AN/AN/A-29.45%-24.24%5/2/2024 (Estimated)
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
-$180.66M-$5.13N/AN/AN/A-669.72%-57.80%-34.14%5/2/2024 (Estimated)
Chimerix, Inc. stock logo
CMRX
Chimerix
-$82.10M-$0.92N/AN/AN/A-25,337.96%-37.93%-35.02%5/2/2024 (Estimated)
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
-$113.30M-$11.68N/AN/AN/A-1,403.15%-199.61%-58.20%5/20/2024 (Estimated)
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$182.39M-$2.72N/AN/AN/AN/A-25.18%-23.99%5/14/2024 (Estimated)

Latest ALDX, XENE, VBIV, BCYC, and CMRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/7/2024Q4 2023
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
-$0.21-$0.08+$0.13-$0.08N/AN/A
2/29/2024Q4 2023
Chimerix, Inc. stock logo
CMRX
Chimerix
-$0.23-$0.20+$0.03-$0.20N/AN/A
2/29/2024Q4 2023
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$0.76-$0.64+$0.12-$0.64$2.30 millionN/A    
2/20/2024Q4 2023
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
-$1.23-$1.16+$0.07-$1.16$11.68 million$5.33 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/AN/A
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
N/AN/AN/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
N/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
N/A
6.64
6.64
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
0.08
8.08
8.08
Chimerix, Inc. stock logo
CMRX
Chimerix
N/A
10.25
10.25
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/A
0.65
0.55
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
23.65
23.65

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
59.71%
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
86.15%
Chimerix, Inc. stock logo
CMRX
Chimerix
45.42%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
12.26%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
7.30%
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
10.20%
Chimerix, Inc. stock logo
CMRX
Chimerix
10.00%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
10.35%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
5.43%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aldeyra Therapeutics, Inc stock logo
ALDX
Aldeyra Therapeutics
1558.90 million54.60 millionOptionable
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
28430.04 million26.98 millionOptionable
Chimerix, Inc. stock logo
CMRX
Chimerix
7289.21 million80.29 millionOptionable
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
19023.69 million21.24 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
25175.43 million71.34 millionOptionable

ALDX, XENE, VBIV, BCYC, and CMRX Headlines

SourceHeadline
Investors Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)Investors Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)
americanbankingnews.com - April 18 at 3:04 AM
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual MeetingXenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
globenewswire.com - April 16 at 8:30 AM
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by AnalystsXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Analysts
americanbankingnews.com - April 16 at 2:34 AM
Xenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at Needham & Company LLCXenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at Needham & Company LLC
americanbankingnews.com - April 14 at 3:36 AM
Needham & Company LLC Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)Needham & Company LLC Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
marketbeat.com - April 12 at 8:14 AM
Cantor Fitzgerald Reaffirms Overweight Rating for Xenon Pharmaceuticals (NASDAQ:XENE)Cantor Fitzgerald Reaffirms Overweight Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
americanbankingnews.com - April 11 at 5:00 AM
Xenon Pharmaceuticals Inc (XENE)Xenon Pharmaceuticals Inc (XENE)
investing.com - April 10 at 12:10 PM
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
globenewswire.com - April 10 at 8:30 AM
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare ConferenceXenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
globenewswire.com - April 4 at 4:01 PM
SG Americas Securities LLC Sells 38,146 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)SG Americas Securities LLC Sells 38,146 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
marketbeat.com - April 2 at 4:18 AM
Assenagon Asset Management S.A. Sells 47,962 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Assenagon Asset Management S.A. Sells 47,962 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
marketbeat.com - April 1 at 4:43 AM
Xenon Pharmaceuticals IncXenon Pharmaceuticals Inc
money.usnews.com - March 21 at 10:13 AM
Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth PlansXenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - March 19 at 8:26 AM
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Wellington Management Group LLPXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Wellington Management Group LLP
marketbeat.com - March 19 at 4:55 AM
XENE Apr 2024 47.500 putXENE Apr 2024 47.500 put
finance.yahoo.com - March 16 at 1:48 PM
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS DaysXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
globenewswire.com - March 12 at 4:01 PM
Insider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells 7,137 Shares of StockInsider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells 7,137 Shares of Stock
insidertrades.com - March 11 at 6:41 AM
Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...
finance.yahoo.com - March 9 at 12:06 AM
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
globenewswire.com - March 5 at 4:01 PM
Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline ProgressBuy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress
markets.businessinsider.com - March 5 at 10:33 AM
Xenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call TranscriptXenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 2 at 2:52 PM
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call TranscriptXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 2 at 9:52 AM
Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - March 1 at 2:30 PM
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in FocusXenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
zacks.com - March 1 at 9:36 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aldeyra Therapeutics logo

Aldeyra Therapeutics

NASDAQ:ALDX
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.
Bicycle Therapeutics logo

Bicycle Therapeutics

NASDAQ:BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Chimerix logo

Chimerix

NASDAQ:CMRX
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
VBI Vaccines logo

VBI Vaccines

NASDAQ:VBIV
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
Xenon Pharmaceuticals logo

Xenon Pharmaceuticals

NASDAQ:XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.